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Abstract
We deduce cell population models describing the evolution of a tumor (possibly interacting with its
environment of healthy cells) with the aid of differential equations. Thereby, different subpopulations
of cancer cells allow accounting for the tumor heterogeneity. In our settings these include cancer
stem cells known to be less sensitive to treatment and differentiated cancer cells having a higher
sensitivity towards chemo- and radiotherapy. Our approach relies on stochastic differential equations
in order to account for randomness in the system, arising e.g., due to the therapy-induced decreasing
number of clonogens, which renders a pure deterministic model arguable. The equations are deduced
relying on transition probabilities characterizing innovations of the two cancer cell subpopulations,
and similarly extended to also account for the evolution of normal tissue. Several therapy approaches
are introduced and compared by way of tumor control probability (TCP) and uncomplicated tumor
control probability (UTCP). A PDE approach allows to assess the evolution of tumor and normal
tissue with respect to time and to cell population densities which can vary continuously in a given set
of states. Analytical approximations of solutions to the obtained PDE system are provided as well.
1 Introduction
Phenotypic and functional tumor heterogeneity is an important feature of neoplastic lesions. During
the last decade there has been increasing evidence that a subpopulation of cancer cells exhibiting the
characteristics of stem cells triggers the initiation and growth of the tumor, also playing an essential
role in metastasis, see e.g., [60] and references therein. According to the cancer stem cell hypothesis,
tumors are initiated and sustained by a small subset of cancer cells with the abilities of self-renewal and
production of differentiated cells of diverse lineages [66]. Depending on the biochemical conditions in the
tumor microenvironment, cancer stem cells (CSCs) can undergo several types of mitosis (see e.g., [12]):
symmetric self-renewal, when both daughter cells keep the characteristics of stem cells; asymmetric self-
renewal, when only one of the daughter cells stays a stem cell, while the other becomes a progenitor cell;
and division into two progenitor cells. Progenitor cells have intermediate properties between stem cells
and differentiated cells; they can divide symmetrically or unsymmetrically, undergoing self-renewal, or
yielding two differentiated daughter cells. While differentiated (progenitor) cells are relatively short-lived,
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having a limited mitotic potential, cancer stem cells seem to have acquired a limitless replicative potential
or immortality [25], thus they are able to persist long enough to accomplish oncogenic mutations and to
migrate and establish new tumors at distal sites in the body. Moreover, cancer stem cells are suspected to
be responsible for the recurrence of the disease after treatment [47, 55]. This is thought to be due to some
cancer cells evolving with the capacity of resistance to chemo and/or radiotherapy [3, 37]. Therefore,
therapies specifically targeting cancer stem cells are likely to be a critical determinant in achieving
complete tumor eradication, see [9] and references therein; we also refer to [13] for a mathematical model
addressing this issue.
A large palette of mathematical models for various aspects of CSC dynamics has been proposed. They
range from deterministic compartmental models involving several types of cells in different stages and
formulated in an ODE framework, see, e.g., [5, 13, 21, 63] to models accounting for spatial effects,
possibly also under the influence of the tumor microenvironment in a discrete, agent-based [17, 16]
or continuous [18, 68] manner. Models also accounting for random effects via transition probabilities
[24, 64], stochastic processes [19], or stochastic differential equations [52] have been proposed as well,
however not all of them considering stemness or phenotype heterogeneity of the cancer cells. Some of
the models mentioned above also relate to the influence of CSC dynamics on chemo and/or radiotherapy
response. While including randomness in the models describing the therapy-free evolution of CSCs in
interaction with differentiated cells (DCs) and normal tissue accounts e.g., for perturbations in the tumor
microenvironment reflecting on the cell population, for cell-to-cell variations or for differences in the
cell cycle stage, in the context of therapy stochasticity becomes a desirable feature of the mathematical
settings: By therapeutical interventions the number of clonogens is supposed to be drastically reduced
(up to eradication), which makes a purely deterministic model questionable. Models involving CSCs
and assessing some kind of applied treatment while explicitly accounting for stochasticity are rarer: For
instance, in [58] the authors use birth-death Markov chains in continuous time to investigate the extinction
times of cancer stem cells and normal stem cells; [39] also used a continuous time, discrete state-space
birth-death process. Iwasa et al. [31] developed a model for acquired drug resistance and determined
the resistance probability of an exponentially growing cell population starting from one sensitive cell and
reaching a given detection size and found that a tumor subject to high rates of apoptosis will show a
higher incidence of resistance than expected on its detection size only. Fakir et al. [19] considered a
stochastic tumor control probability (TCP)1 model incorporating repopulation of stem-like cancer cells
and their mutual interactions within microenvironmental niches. The TCP is computed upon relying on
probability distributions of a prespecified shape and corresponding survival and repopulation matrices
involving niche-endogenous birth and death rates. Continuum SDE models for the evolution of tumor
cells offer a way to account for intrinsic and extrinsic uncertainties in connection to CSCs and their
interactions with DCs and normal tissue. SDE models used in the context of cancer growth and assessing
the TCP and the probability distributions of times to extinction for the considered populations of cancer
cells were proposed in [65] and later in [40].
In this work we introduce a class of SDE models describing the interplay between CSCs and tumor
DCs. Their formal deduction is presented in Section 2 and follows the method proposed by Allen, see
e.g., [2], and also used in a first form in [40]. However, an essential modification is done here in order
to ensure non-negativity of the solutions. The restrictions imposed by the latter actually guide the
modeling in this framework. For these models we perform numerical simulations in order to illustrate
the (pathways and averaged) behavior of the two subpopulations of interacting cancer cells. In Section 3
we extend the settings to account for therapy, thereby looking both at a time-discrete approach and its
continuous counterparts. Several different treatment schedules involving chemo and/or radiotherapy are
considered. Section 4 is dedicated to assessing the various treatment strategies applied to the DCs and
CSC populations. The subsequent Section 5 proposes a model version supplementary accommodating the
dynamics of the normal cells. For the new model we evaluate in Section 6 the therapy effects on normal
cells with the aid of the normal tissue complication probability (NTCP) and the overall treatment efficacy
by way of the uncomplicated tumor control probability (UTCP). Section 7 provides a PDE approach to
assessing the future evolution (in the mean) of the tumor and normal tissue based on the tumor state
known at some given moment of time. Such prediction of the tumor evolution is of high relevance
for the patients and for clinical trials, as it helps to estimate and compare the disease evolution under
diverse classes of a tumor staging system or different treatments. Thereby, the quantities of interest
here are expectations of the total tumor burden, its stemness portion, and the deviation of normal
tissue from a critical functionality threshold. A way to derive analytical approximations in closed-form
1The TCP gives the probability that no clonogenic cells survive the treatment.
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for such quantities is also presented. The method can be extended to predict other interesting future
numerical characteristics of the tumor (e.g., its standard deviation or survival probabilities for some
given thresholds). Moreover, the proposed PDE approach is less time consuming and numerically more
efficient than the standard one based on simulating the SDE system. We deduce the corresponding linear
and nonautonomous PDEs, solve them numerically, and also provide analytical approximations of the
solution components. Finally, in Section 8 we provide some comments on the perspectives of our modeling
approach.
2 An SDE model for a heterogeneous tumor without treatment
2.1 Model setup
We derive an SDE model for the differentiated cancer cells and the cancer stem cells. To this aim, let
c(t) and s(t) denote the population sizes of the former and of the latter, respectively, at time t. We want
to analyze the interactions between these two populations and are going to proceed as in [2]. We make
the following assumptions (see also [27]):
1. Cancer stem cells are immortal and have unlimited replicative potential, see e.g. [44] and references
therein.
2. As mentioned in Section 1, each of the cancer stem cells is able to divide in various ways; for
simplicity, we assimilate in the respective subpopulation progenitor to differentiated cells:
• into two stem cells (with probability a1),
• into one differentiated cancer cell and one cancer stem cell (with probability a2) or
• into two differentiated cancer cells (with probability a3)




The probabilities ai are commonly chosen to be constants, however in order to ensure the non-
negativity of solutions to our model (1) below, we will require a2 and a3 to be proportional to
the density c of differentiated cancer cells. Indeed, there is evidence of the latter influencing the
CSC dynamics and their properties [45, 57]. We postulate that the differentiation of CSCs into
DCs is favored by the two phenotypes being in contact (while the direct birth and death of either
phenotype are not influenced by other processes) and choose here
ai(c) =
ãic
ã1 + ã2c+ ã3c
, i = 2, 3, a1(c) =
ã1
ã1 + ã2c+ ã3c
with ãi being positive constants. Other choices are possible as well, the only restriction being that
ai(0) = 0 for i = 2, 3 and
3∑
i=1
ai(c) = 1. Moreover, as in previous models, e.g. [11, 26, 27] we assume
the differentiation process to be irreversible.
3. Differentiated cancer cells are mortal and have a finite potential to divide.
4. During proliferation differentiated cancer cells divide into two cells, each of them being again a
differentiated cancer cell.
The relevant occurrences in connection with the differentiated and stem cell dynamics in a tumor can be
described schematically as in Figure 1.
The parameters used above have the following meaning: bc: proliferation rate of c-cells (symmetric
differentiation only); bs: proliferation rate of stem cells (with the three possibilities enumerated in 2.
above), and ds, dc: death rates.
The above assumptions lead to bs, dc > 0, ds ≥ 0, bc = 02. For a small interval of time of legth ∆t
(such that the envisaged changes happen independently of each other; in particular we also assume that
2Actually, bc becomes negligible after a few differentiations; in order to simplify the computations we directly assume
bc = 0, see also [27]. The stem cells are practically immortal (see our first assumption above), thus we could set ds = 0.
In Section 3, however, we will also take into account death rates which are not inherent to the population, but are due to
treatment application, hence there a death rate ds > 0 will be considered.
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differentiation events do not happen simultaneously to birth and death in the s-population) we register
in Table 1 the respective transition probabilities for X = (c, s)t, upon relying on the scheme in Figure 1.
Figure 1: Interaction of differentiated cancer cells c and cancer stem cells s.
Changes in X Probability
∆X(1) = (1, 0)t p1 = a2(c)bss∆t
∆X(2) = (−1, 0)t p2 = dcc∆t
∆X(3) = (0, 1)t p3 = a1(c)bss∆t
∆X(4) = (0,−1)t p4 = dss∆t
∆X(5) = (2,−1)t p5 = a3(c)bss∆t
∆X(6) = (−1, 1)t p6 = dcca1(c)bss∆t
∆X(7) = (2, 0)t p7 = 0
∆X(8) = (−1,−1)t p8 = dccdss∆t
∆X(9) = (1,−1)t p9 = bccdss∆t = 0
∆X(10) = (1, 1)t p10 = bcca1(c)bss∆t = 0
∆X(11) = (3,−1)t p11 = 0
∆X(12) = (0, 0)t p12 = 1−
∑11
i=1 pi
Table 1: Transition probabilities for X = (c, s)t, according to the scheme in Figure 1.







(a2(c(t)) + 2a3(c(t)))bss(t)− (a1(c(t))bs + ds)dcc(t)s(t)− dcc(t)






















u = dcc(t) + (a2(c(t)) + 4a3(c(t)))bss(t) + (ds + a1(c(t))bs)dcc(t)s(t),
v = −2a3(c(t))bss(t) + (ds − a1(c(t))bs)dcc(t)s(t)
w = dss(t) + (a1(c(t)) + a3(c(t)))bss(t) + (ds + a1(c(t))bs)dcc(t)s(t).




is positive-definite. Hence the square root of the matrix V exists and we denote it by B := V1/2. Further






(a2(c(t)) + 2a3(c(t)))bss(t)− (a1(c(t))bs + ds)dcc(t)s(t)− dcc(t)













The matrix B can be explicitly computed (see e.g., [2]):














uw − v2 and η =
√
u+ w + 2τ . The system of stochastic differential equations for the
dynamics of the two cancer cell populations is then given by
dX = µ(X)dt+ B(X)dW(t)
with the initial condition X(0) = X0 and W(t) = (W1(t),W2(t))
t, where (W1(t))t and (W2(t))t denote
independent Wiener processes. Thus for each population we obtain
dc(t) = µ1(c, s)dt+B11(c, s)dW1(t) +B12(c, s)dW2(t)







ds(t) = µ2(c, s)dt+B21(c, s)dW1(t) +B22(c, s)dW2(t)








Thereby, (c(t))t and (s(t))t are stochastic processes for which every trajectory describes the evolution of
a specific tumor, hence the disease development in a specific patient - if we assume each patient has a
single tumor. Thus, X = (c, s)t : Ω× (t0, T )→ (0,∞)2, with (Ω,A,P) being a filtered probability space
for which Ω denotes the sample space, i.e. a set of tumors/cancer patients.
Remark 2.1 The well-posedness of (1) supplemented with initial conditions
c(0) = c0, s(0) = s0 (2)
with c0 and s0 positive, nonanticipative random variables is not obvious, as the drift and diffusion
coefficients are only locally Lipschitz. We refer to [61] for an existence result in the case where µ and B
are only continuous. The uniqueness needs to be treated separately and there are several works handling
this issue, thereby using various notions of uniqueness. When the drift and diffusion coefficients are,
however, locally Lipschitz, then strong uniqueness follows, see e.g. [35].
The non-negativity of solutions to our SDE system follows directly from a result by Cresson et al. [10]
providing necessary and sufficient conditions for the invariance of rectangular subsets, which we recall for
convenience in Subsection 9.1.
2.2 Numerical simulations
In order to simulate our system of SDEs (1) we consider the example of glioma, which are rarely curable
brain tumors arising from abnormal glial cells in the human brain, with poor prognosis (the median
survival time is about 14 months). We take the birth rate of untreated tumor stem cells to be only
very slightly less than the corresponding median value obtained in [62] for glioma, namely bs = log 2/55.
In that paper only one glioma phenotype was observed, thus not distinguishing between stem cells and
differentiated cells. As we assumed above that bc = 0, this seems to be justified. For the DCs we assume
that their death rate is smaller than the mitosis rate of stem cells, and take dc = log 2/60. The death
rate ds of CSCs is taken very small, in accordance with the assumptions in Section 2.1. The different
rates involved in the probabilities of the CSCs to differentiate are ã1 for the symmetric division into two
CSCs, ã2 for the asymmetric division into one DC and one CSC, and ã3 for the division into two DCs.
Compared to the symmetric divisions of cancer stem cells, the asymmetric one is much rarer, and is
occasionally even neglected (see [26]). We will not completely neglect it, since in our model this would
mean that once the DCs get extinct there is no chance of producing any new DCs from the CSCs, which
would contradict the biologically well-established fact that tumor relapse can occur from small amounts
of stem cells [33]. The parameters used to simulate (1) are collected in Table 2.
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Parameter bs dc ds ã1 ã2 ã3
Value log 2/55 log 2/60 log 2/200 0.5 0.05 0.1
Table 2: Summary of the model parameters for cancer cells based on [62].
Some trajectories of our SDE system solved with the Euler-Maruyama method and the average over 103
such trajectories are shown in Figure 2.
Figure 2: Several trajectories of the solution components of system (1) and averages (black lines) of 103
trajectories solved with the Euler-Maruyama algorithm and using parameter values as in Table 2.
Initial condition: (c, s)t = (0.9, 0.1)t.
2.2.1 Approximation of the persistence time
An important aspect of two interacting populations is their long-term behavior, especially the persistence
time, i.e. the time it takes for one of the two populations to become extinct. As we consider a system
of SDEs it makes sense to look at the mean persistence time of the joint populations. To compute it, we
simulate the behavior of the two tumor cell phenotypes described with the aid of the SDE (1) and trace
the trajectories until the whole population first becomes extinct. This simulation has to be carried out
several times so that we can average the persistence times.
Concretely this means that we generate a large enough number of trajectories (here 1000) by solving (1)
with the Euler-Maruyama method over a time span of 70 days. These trajectories are stopped whenever
we have c+s ≤ 0 and we note the exact time of this event. Averaging the data computed with the choice
of parameters from Table 2 we obtain estimations for several different compositions of the initial tumor3,
which we collected in Table 3.
Obviously, the computed persistence times are larger when starting with larger tumor cell populations.
Just by computing the persistence times is, however, difficult to say whether the tumor heterogeneity
plays a role, since these times are only very slightly different when starting with the same overall joint
amount of neoplastic cells (compare 3rd to 11th rows in Table 3). They seem to correlate directly with
the initial CSC density and inversely with the initial amount of differentiated cells, but there seems
to be a balance between these values and the total initial amount is, of course, essential. Biological
evidence as reviewed in Section 1 tells, however, that targeting the CSCs should enhance the therapeutic
outcome, which is also is suggested by the very simple deterministic model in [13]. We also want to
investigate this issue in our stochastic framework. To this aim we study therapy approaches which only
use a differentiation promoter and compare them with those also aiming at cell killing by radiotherapy.
3by this we mean amount of CSCs and DCs at the initial time, i.e. at the first tumor assessment time; this could be the
time of first diagnosis. We do not mean the time at which the tumor started to develop, as that cannot be inferred, and
even less its proportions of CSCs and DCs
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Table 3: Persistence times for the whole tumor c+ s, averaged over 1000 trajectories, for different
compositions (c, s) of the initial tumor.
3 Including treatment
Cancer stem cells have been identified in many tumors as the driving force behind cancer growth as well
as cancer progression [26]. Consequently, effective treatment schedules and strategies should affect the
differentiated cancer cells as well as the cancer stem cells. The eradication of CSCs is rather difficult, as
these cells are less sensitive to radiation or chemical agents in comparison to DCs [50]. Moreover, it is
difficult to identify these cells in vivo, as they are spread all over the tumor [68].
An important consequence of cancer treatment is the increase of the death rates dc and ds for both
types of cancer cells. In this section we present and illustrate the main therapy concepts by showing
their respective effects on the tumor cells only. Their application to the tumor and normal cells will be
addressed in Section 5.
3.1 Chemotherapy: differentiation promoters
In chemotherapy different cytotoxic agents affect the death rate of the DCs as well as that of CSCs,
depending on the treatment dose. CSCs are less sensitive to this treatment, resulting in a lower death
rate in comparison to the DCs [50].
Here we present an approach to model the so-called differentiation therapy. Here the aim is to induce the
cancer cells to resume the process of maturation. This kind of therapy does not directly kill the cancer
cells, but restrains their growth and allows the more efficient application of conventional therapies to
eradicate the tumor. Thereby, the sensitivity of cancer stem cells is enhanced by adding differentiation
promoting agents. Possible promoters are members of the TGF-β superfamily which are known to affect
the characteristics of growing tumors like invasion and immune evasion, and most important (as men-
tioned), the increase of stem cell differentiation [26].
In our model from Section 2.1 this would imply decreasing the probability a1 which characterizes the
splitting of a cancer stem cell into two cancer stem cells, and increase the probability a3 for the differ-
entiation of a cancer stem cell into two differentiated cancer cells. Here we focus on the fact that the
rate a3 depends on the parameter δ related to the dose of the chemical differentiation promoter delivered
during the treatment. Thus, we get
a3 = a3(c, δ) =
ã3(δ)c
ã1 + ã2c+ ã3(δ)c
, with ã3(δ) = ã3 +
α̃δ
1 + δ
, α̃ > 0, (3)
where ã3 is the value in the case without therapy and α̃ is a sensitivity parameter. For instance, drugs
targeting histone deacetylases (HDACS) are already being used to enhance differentiation or reprogram-
ming events; we refer to [46] for a review of epigenetic alteration agents involved in CSC reprogramming.
A treatment approach in a phase I study is to deliver 200 mg bid per day of SAHA (vorinostat) on 7
days a week, with one treatment cycle of 4 weeks [36]. Low grade gliomas have diameters between 1 and
6 cm (occasionally even larger), see e.g., [7]. We choose an early stage tumor with a diameter between 1
7
and 2 cm, hence a reasonable dose in a tumor of diameter 1.2 cm can be assumed to be δ = 0.05625 mg.4
In addition to a change in differentiation rates, the chemotherapy also influences the cell death rate
depending on the dose. We assume an increase in the death rate for the differentiated cancer cells with
0.015, which is comparable to the one in [53]. Due to the fact that cancer stem cells are less sensitive to
this supplementary therapy effect we only increase the death rate with ds = 10
−4.
Figure 3: Different trajectories of the SDE system (1) and their averages (thick black lines) for 103
trajectories when applying chemotherapy. Parameter values as in Table 2, dose-dependent probability
a3 of symmetric splitting of a cancer stem cell into differentiated cells as given in (3). Upper row:
α̃ = 0.5, lower row: α̃ = 10 .
Trajectories obtained by numerical simulations with the Euler-Maruyama method for widely different
values of the sensitivity parameter α̃ are shown in Figure 3. The sensitization on CSCs effects a slightly
reduced growth in their density, while the DCs are depleted to a certain, however not very large amount.
For (much) larger values of α̃ there is even less increase in CSCs (but no effective decrease) and almost
no further effect on DCs, but the concrete choice of this parameter seems to be hardly of relevance with
respect to the efficacy of reducing the overall tumor burden when the effect of the chemotherapeutic
agent is mainly aiming at sensitizing the cancer cells by inducing differentiation of CSCs. The behavior
of CSCs and DCs is shown including the follow-up time of 42 days after the end of this treatment. The
depletion is too low (compare also with Figure 2 showing no therapy at all), as the cancer stem cells are
known to trigger recidives even when present in a very low amount [33]. Therefore this approach alone is
not enough to control the tumor: The differentiation promoter should be used in an adjuvant way with
other therapies, e.g. ionizing radiation.
3.2 Radiation therapy
When applying radiotherapy proliferating cells are harmed by altering their genetic material. Depending
on the cell type and the cell’s current position in the cell cycle, its radiosensitivity varies.
The most common approach for modeling the radiation treatment of a tumor is the LQ-model based on
4for simplicity we assume this to be constant
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a linear-quadratic exponent to describe the effect of the therapeutic dose on cell survival fractions: A cell
survives applied doses of radiation (and is said to be a clonogen) if it is able to act as a progenitor for a
significant line of offspring [11]. The fraction of surviving cells S(D) after a single total dose D (in Gray)
is then given by (see e.g., [4])
S(D) = e−(αD+βD
2) (4)
for parameters α, β that correlate with the cell cycle length. The parameter α can be interpreted as the
lethal damage due to a single track of radiation and the parameter β represents lethal damage due to the
misrepair of DNA damage as a result of two separate tracks of radiation [26]. Tissues with a slow cell
cycle correspond to a small α/β-ratio, whereas fast cycling tissues containing quickly proliferating cells
correspond to a larger α/β-ratio. In common clinical practice the total dose D is given in ν fractions of
equal size d [4]. From the corresponding hazard rates
di = (αi + βid)d for i = c, s (5)
we obtain the death rates involved in system (1). Unlike chemotherapy in the previous section, the
treatment with radiation includes weekend breaks. A common daily radiation dose is d = 2 Gy during
ν = 25 days of treatment (hence a total dose of 50 Gy, leading to an overall treatment time of 5 weeks [4].
To simulate this therapy strategy we choose the sensitivity parameters in Table 4. The obtained results
are shown in Figure 4.
Parameter α (in Gy−1) βc (in Gy
−2) βs (in Gy
−2) d (in Gy) ν (in days)
Value 0.0906 0.006 0.00605 2 25
Table 4: Model parameters for radiation therapy based on [54, 67], where no difference was made
between various phenotypes of tumor cells. The parameter βs was chosen here slightly larger than βc to
account for the reduced sensitivity of CSCs towards therapy.
Figure 4: Different trajectories of the solutions components of system (1) with the application of
radiation therapy and their averages (thick black lines) over 103 trajectories. Parameter values as in
Tables 4 and 2, follow up to 70 days.
A closely related concept to the LQ-model is the Biological Effective Dose (BED) [4]. This quality








with the dose d per fraction and the number of fractions ν. We will use this quantity in Subsection 3.4 to
describe therapy applying irradiation doses at discrete times, alone or in combination with the continuous
application of a cell differentiation promoter.
3.3 Combining chemotherapy and radiotherapy
Most patients undergo tumor resection for diagnostic and treatment purpose, however postoperative
treatment strategies like radiation and chemotherapy are needed to further reduce tumor progression and
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ideally prevent recurrence. Thereby, they can be used in a consecutive or concurrent way; the latter
option seems to be often the better choice [6, 20]. Clinical trials aiming at the investigation of such com-
bined effects have been set up; for instance, the use of vorinostat together with radio and chemotherapy
(cisplatin) in the treatment of advanced staged oropharyngeal squamous cell carcinoma makes the object
of a phase I study (ClinicalTrials.gov identifier NCT01064921). Studies of histone deacetylase inhibitors
as anticancer drugs in combination with radiotherapy have been performed for a large variety of cancers,
including glioblastoma, see [15] and references therein.
In our model we consider the joint application of a differentiation promoter (e.g., vorinostat) and of
radiotherapy. As mentioned above, the main effect of chemotherapy is the stimulation of differentiation
into cells which are more sensitive towards radiotherapy, thus boosting the cell kill. However, the ad-
ministered drug can also induce a modest cell depletion by itself, hence enabling us to add some tiny,
but positive constants to the previous death rates ds and dc used in our model obtained in Section 2.
For simplicity we consider a simulation based approach and do not incorporate a decay term modeling
radiation therapy via the LQ model into our system of SDEs, but simply apply formula (4) to the CSC
and DC volume fractions at scheduled times during computation. The simulation is stopped at the times
of radiation treatment, S(D) is applied to c and s using the corresponding values for α and β, and then
the simulation is resumed. The radiotherapy is applied 5 days a week, 5 weeks, with a daily dose of 2
Gy, resulting in a total therapy time of 35 days. Chemotherapy (sensitization) follows the approach in
Subsection 3.1 above and involves the same dose therein, applied daily in a concurrent way during the
time span of 4 weeks and during all weekdays. The administration of the chemotherapeutic agent leads
to an increase in the number of CSCs dividing symmetrically into DCs and thus becoming more sensitive
to radiation. Simulations of this combined treatment strategy are shown below in Figure 5. Just by
visually comparing this with Figure 4 it is difficult to decide whether radiotherapy gives better results
alone or in simultaneous combination with a differentiation promoter.
(a) (b)
Figure 5: Trajectories of the SDE model (1) with the simultaneous application of radio- and
chemotherapy (differentiation promoter) and their averages (thick black lines) over 103 simulated
trajectories. Parameter values as in Tables 4 and 2, with α̃ = 10, follow up to 70 days.
A further common way to integrate different cancer therapies is to alternately apply chemotherapy (in our
case differentiation promoter of CSCs into DCs) and ionizing radiation. Thereby, an often used schedule
is to apply three to four weeks of chemotherapy followed by radiotherapy. Here a differentiation promoter
is administered for 4 weeks and subsequently radiotherapy is applied for 5 weeks, only on workdays, to
achieve a total dose of 50 Gy in fractions of 2 Gy each. The parameters are chosen in accordance with
the previous Subsections 3.1 and 3.2. The results of the corresponding simulations are depicted in Figure
6.
Upon comparing the two approaches involving combined chemo- and radiotherapy we observe that the
consecutive application seems to be less efficient than the concurrent one.
3.4 Time-discrete therapy
Up to now we have considered the development of the population sizes of cancer stem cells and differ-
entiated cancer cells for continuous therapies. However, no treatment schedule is actually continuous,
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(a) (b)
Figure 6: Different trajectories of the SDE model (1) with the alternating application of chemotherapy
and radiation therapy and their mean values (thick black lines) for 103 simulated trajectories.
Parameter values as in Tables 4 and 2, with α̃ = 10, follow up to 70 days.
(a) (b) (c)
Figure 7: Trajectories of (1) and their averages (thick black lines) over 103 simulated trajectories with a
time-discrete radiotherapy solved with the Euler-Maruyama scheme, parameter values as in Table 2.
Subfigures 7(a) and 7(b) show the results of the simulation for the two subpopulations of cancer cells





therefore we model a time-discrete approach involving chemo and/or radiation therapy, in a way that
it is typically applied to patients, i.e. at discrete points in time - for example: once a day, except for
weekends.
To this aim we select a sequence of points in time {tk}k=1,...,N with 0 < t1 < . . . < tN at which the
treatment is administered. Further let ξ1, . . . , ξN be a sequence of i.i.d. random variables characterizing
the effect of therapy on the tumor cells. Thus, the random variable ξk corresponds to the treatment at
time tk. The process Lt describes the (cumulative) effect of the treatment on the respective cell types





0 , if 0 ≤ t < t1∑
{k: tk≤t} ξ
(j)
k , if t1 ≤ t.
j = c, s. (7)
Thereby we set ξ
(j)










with BED(j) representing the biological effective dose from (6) computed for αj/βj , the parameter values
σD = 0.1, d = 2 Gy, and the corresponding sensitivity parameters αj , βj (j = c, s) as in Table 4.
Next we need a couple of stochastic processes Rc(t) and Rs(t) that characterize the population sizes of
the differentiated cancer cells and the cancer stem cells upon application of therapy:
Rc(t) = c(t)e
−εcL(c)t , Rs(t) = s(t)e
−εsL(s)t (9)
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for t ≥ 0 with small constants εc, εs > 0 (here we choose εc = 0.0004, εs = 0.0002 to account for
the stem cells being less sensitive). The choice of the noncentral parameter of the χ2 distribution is
motivated by the proportionality between the mean of ξk and the dose d; this dependence is analogous
to that for the survival fraction, hence (9) actually describes the effect of radiotherapy (LQ model) on
the respective population of tumor cells. In order to simulate this model we need some distributions
and parameters that we choose similarly to Section 2.2, Table 2. When applying radiotherapy alone or
simultaneously to the continuously applied differentiation promoter we start the radiation treatment at
time t1 = 1 and continue on every workday, for 5 weeks, if applicable administering during the weekends
the chemotherapeutic agent for cancer cell sensitization. Simulations of the application of radiotherapy
alone are depicted in Figure 7. In this case, too, after the end of treatment the cancer cells (especially
CSCs) multiply further and trigger recurrence of the tumor, so that applying a differentiation promoter
is expected to lead to a better outcome.
The application of radiotherapy at discrete times can also be combined in an alternative way with
the continuous administration of differentiation promoter (i.e. first chemotherapeutic sensitization by
differentiation promoter for 4 full weeks, then radiotherapy applied once a day during the 5 weeks following
chemo, only on workdays). In the next section we will assess the effects of these and the previous
approaches by way of TCP.
4 Treatment assessment via TCP
A common quality measure for the success of a treatment schedule is the tumor control probability
(TCP), which gives the probability that no clonogenic cell survive radiation treatment. It is deter-
mined by complex interactions between tumor biology, tumor microenvironment, radiation dosimetry,
and patient-related variables. The complexity of these joint factors constitutes a challenge for building
predictive models for routine clinical practice.
Most TCP models rely on simple statistics connected to cell survival. Among these, the model considering
a discrete distribution (Poisson or binomial) for the number of cells surviving radiation treatment is –due
to its simpliciy– very popular, see e.g., [8]. These settings, however, cannot capture many of the features
related to the specific treatment schedules, like cell repair, proliferation, sensitivity to radiation etc. Cell
population models describing the evolution of the tumor cell density via differential equations offer a
way to overcome these drawbacks, but most of those considered so far are purely deterministic, hence
adequate only for large cell populations. By anti-cancer therapy, however, such a population is supposed
to shrink drastically, so that only a small number of cells remains. As already mentioned in Section 1, this
renders the use of a deterministic model questionable, thus calling for the accommodation of stochasticity
in the modeling process. Settings accounting for uncertainties via stochastic birth and death processes
have been proposed e.g., by Zaider and Minerbo [69] and extended e.g. in [11, 22]; they lead eventually
to a system of ODEs, which are the mean field equations for the expected cell density -thus carrying, in
fact, the assumption of large cell populations- and where the effect of the birth and death processes is
captured via a hazard function. Here we assess the TCP from our SDE models introduced above, thereby
relying for its computation on numerical simulations, as a closed form expression of the TCP (as obtained
e.g., in [11, 22]) seems to be out of reach, given the complexity of such formulations. We denote by τc+s
the first time when the stochastic process characterizing the overall tumor cell population first becomes
zero and compute (following the idea in [65])
TCP(t) = P(τc+s ≤ t), t ≥ 0. (10)
This implies that the TCP is the cumulative distribution function of the random variable τc+s. Based
on (10) we can thus compute the TCP upon performing a large number Q of simulations for the process
(c+ s)(t):
TCP(t) =
number of simulations with τc+s ≤ t
Q
, (11)
which is a probability that converges to TCP(t) for Q → ∞. The results are shown in Figure 8. The
comparison between TCPs for the different therapy approaches gives some hints on which of these might
be more effective with respect to tumor eradication.
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(a)
Figure 8: TCP for the different therapy strategies based on (1), with 103 simulations.
However, the treatment should not have the single aim of eradicating the neoplastic tissue; preserving as
much healthy tissue as possible is of utmost importance as well. Therefore, the effects of therapy on the
normal tissue have to be included in the models. They are influenced, too, by the stochasticity inherent
to the system and are addressed in the next section.
5 SDE formulation accounting for the effects on normal tissue
Analogously to Section 2.1 we can derive an SDE for the normal cell density:
dn(t) = (bn − dn)n(t)dt+
√
(bn + dn)n(t)dW (t) (12)
with initial conditions n(0) = n0 and the Wiener process W (t) assumed to be independent of W1(t) and
W2(t) in (1). The dynamic death rate dn is defined as
dn(t) = hn(t) + δn(t)(Sc(D)c(t) + Ss(D)s(t)), (13)
where δn(t) characterizes the interaction between normal tissue and tumor cells, which is known to
be destructive for the former, due e.g. to tumor-induced hypoxia and the effects of matrix degrading
enzymes. However, only living tumor cells can degrade the normal tissue, therefore we have to include
the survival fractions for both cancer cell phenotypes, according to their sensitivities toward the applied
treatment. When no radiotherapy is applied we take Sc = Ss = 1. We further assume that in the time
span of interest the natural decay of normal tissue (i.e. without any influence of therapy or cancer) is
negligible. The term hn(t) describes normal tissue necrosis due to therapy; concretely, hn(t) denotes the
hazard rate of normal cells and can be seen as an intrinsic risk of being degraded by therapy. A classical
choice is hn(t) = −(ln(S(t)))′, where S(t) represents the dynamic survival fraction of normal cells under
therapy, see e.g., [59]. When considering therapy according to the LQ model this leads to
hn(t) = (αn + 2βnD(t))Ḋ(t),
with the positive constants αn and βn denoting as before the sensitivity parameters and D(t) being the
total dose absorbed at time t. Analogous formulae hold for the other cell subpopulations (CSCs and
DCs) as well (with corresponding sensitivities αi and βi, i = c, s). When the total dose is fractionated,
i.e. D = νd, then in [23] the hazard rate was proposed to take the form
hn(t) = (αn + βnd)Ḋ(t). (14)
Furthermore, considering as in [22] ti (i = 1, . . . , ν) the starting time of each fraction and assuming the
doses are delivered during the time interval [ti, ti + RT ] with a constant amount d in each fraction (RT
denotes thereby the fraction length, here RT = 1), following [22] we arrive at
Ḋ(t) =
{




which makes of (14)
hn = (αn + βnd)d.
The survival fractions are modified correspondingly to account for this fractionation, so that for each
treatment fraction we use Sc(d) and Ss(d) in (13). With this the death rate in (13) is completely
specified and we turn our attention toward the birth rate bn in (12). Aligning to a logistic growth model







, if n(t) ≤M
0, otherwise
, (15)
to be the birth rate if n(t) normal cells are alive. This implies that the normal cell growth is limited
by growth factors like space and nutrient supply. Due to this definition an increasing population size
leads to a decreasing birth rate. With this choice the amount of normal cells would always stay below
the carrying capacity M if we would only examine the deterministic model. Setting bn(t) = 0 whenever
n exceeds the carrying capacity (which can happen when describing stochasticity upon using a Wiener
process) a too large increase of the normal tissue is prevented.
Observe that the dynamics of normal cells is (unidirectionally) coupled to that of CSCs and DCs via
decay induced by the interaction between healthy and neoplastic tissues. Thus, in order to assess the
evolution of n(t) we need to solve the SDEs for c(t) and s(t) introduced and handled in Sections 2 and
3. Numerical simulations of solutions to (12) with the coefficients described above are shown in Figure
9 for the case with no therapy. Thereby we introduce a threshold density for the normal tissue: If the
latter falls below that threshold, then the respective area affected by the tumor is assumed to no longer
function. From this point on we will fix this threshold to γ = 0.7, meaning that the affected region will
collapse when less than 70% of its constituent tissue is functional. Notice that without therapy (i.e. for
hn(t) = 0 and Ss = Sc = 1 in (13)) the (average) normal tissue density will reach the threshold γ in more
than the observed 70 days. The next step will be to take treatment into account.
Parameter Description Value
µn constant maximum birth rate (in day
−1) 0.01
δn interaction factor 0.002
γ threshold of functionality 0.7
n0 initial density of normal tissue 1
M actual carrying capacity (normalized) 1
Table 5: Model parameters for normal tissue (without therapy).
Figure 9: Trajectories of (12) for normal tissue density and of CSCs and DCs as solutions to (1). Their
averages over 103 trajectories are shown as thick black lines. Parameter values are given in Table 5.
The dotted grey line represents the threshold value γ for the normal cell density.
The application of chemotherapy (only aiming at CSC differentiation into DCs) does not explicitly alter
the equation in our model (12). However, it affects indirectly the normal tissue density, on the one hand
by reducing the amount of tumor cells and thus decreasing the normal tissue degradation, but on the
other hand due to the side effects of the differentiation promoter it can also degrade a certain (very small)
amount of tissue. Simulations of the behavior of normal cells with a differentiation promoter therapy as
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described in Section 3.1 are shown in Figure 10. Only very small differences between the situation with
no therapy and that with application of the differentiation promoter can be observed; the cancer cell
densities seem to be slightly reduced when therapy is applied, while the normal cells are hardly affected.
In average the normal tissue maintains its function beyond the time span of the treatment schedule (4
weeks).
Figure 10: Trajectories of (12) for normal tissue density and of CSCs and DCs as solutions to (1) for
the differentiation therapy approach in Section 3.1, with α̃ = 10. Their averages over 103 trajectories
are shown as thick black lines. Parameter values are given in Table 5. The dotted grey line represents
the threshold value γ for the normal cell density.
Now including radiotherapy (i.e. taking a nonzero hazard rate hn(t)) increases the death rate of normal
tissue. We consider as before several treatment approaches, including radiotherapy alone or in com-
bination with the differentiation promoter, in concurrent or alternating ways. Time-discrete scenarios
are also considered: Figure 11 shows simulations of the densities of normal cells, cancer stem cells, and
differentiated cancer cells for these approaches. In the time-discrete case we illustrate in Figure 12 the
outcome for radiotherapy applied at discrete times (on 25 days, once a day, during workdays, each dose
2 Gy), alone or in combination with differentiation therapy applied continuously for a period of 4 weeks
and for an alternating therapy with differentiation promoter applied continuously for 4 full weeks, fol-
lowed by time-discrete radiotherapy applied for 5 weeks (working days only, 2 Gy once per day). For the
simulations we use the parameters from Tables 5 and 6.
Parameter Description Value
αn sensitivity parameter (in Gy
−1) 0.0025
βn sensitivity parameter (in Gy
−2) 0.003
Table 6: Model parameters for radiotherapy affecting normal tissue, based on [22].
6 Treatment assessment: NTCP and UTCP
Normal tissue complication probability (NTCP) and uncomplicated tumor control probability (UTCP)
are two further measures for the quality of treatment. They aim at assessing its damaging influence on the
normal tissue alone (NTCP) and jointly on tumor cells and normal tissue (UTCP). NTCP is generally
defined as the probability that the functioning of normal tissues is impaired by exposure to ionizing
radiation and is hence to be kept as low as possible. There are quite a few approaches to computing
NTCP for diverse treatment schedules described in a deterministic way or including stochasticity via
birth and death processes, see e.g., the Lyman model [43] using dose-volume histograms and applicable
to uniform dose distributions, its adaptation to nonuniform distributions done in [41], further extensions
like the critical volume NTCP model [32, 48] accounting for the tissue structure, i.e. whether parts of it
can still function if the rest is damaged, and the model presented in [22] relying on simple birth and death
processes and allowing to compute the NTCP by way of generating functions or numerical simulations.
The method applied in [64] to determine a formula for NTCP cannot be used here, as our framework is
more complex and does not allow to perform the assumptions made therein. In the following we therefore





Figure 11: Trajectories of the SDE (12) and of system (1) and their averages (black lines) over 103
trajectories. Parameters as in Tables 2, 4, 5 and 6. Plots 11(a)-11(c): effect of radiation therapy only.






Figure 12: Trajectories of the SDE (12) and of processes c(t), s(t) obtained by applying time discrete
therapy: radiotherapy alone (plots 12(a)-12(c)); in a concurrent (plots 12(d)- 12(f)) or an alternating
way (plots 12(g)-12(i)). Averages over 103 trajectories are shown in thick black lines. Parameters as in
Tables 2, 4, 5 and 6.
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NTCP computation for an SDE model In analogy to Section 4 we denote by τn the random
variable registering the times when n(t) first drops below a specific threshold value γ. This threshold γ
describes as in Section 5 the minimum amount of normal tissue necessary for a specific organ to function
properly. Then the probability that severe complications occur in the healthy tissue is given by:
NTCP(t) = P(τn ≤ t) t ≥ 0. (16)
This implies that the NTCP is the cumulative distribution function of the random variable τn. As our
differential equations are quite complex we cannot explicitly compute a formula for the NTCP but we
can approximate it numerically.
Based on (16) we can compute the NTCP upon simulating a large number Q of trajectories for the
process n(t) denoting for the volume fraction of healthy tissue and obtain
NTCP(t) =
number of simulations with τn ≤ t
Q
, (17)
which converges to NTCP(t) for Q→∞. Simulating the NTCP via the SDE model and with parameters
given in Tables 5 and 6 we obtain the results presented in Figure 13. As expected, the time-discrete
Figure 13: NTCP for the different therapy strategies based on SDEs, 103 simulations.
therapy approaches seem to be the more conservative ones. The mere use of a differentiation promoter
is the approach least damaging the normal tissue, but it is also least efficient in killing cancer cells,
while time-discrete approaches are comparable. A high efficiency in tumor cell depletion is unfortunately
impairing the functionality of normal tissue, therefore another quality measure is needed to assess the
performance of a therapeutic approach.
Uncomplicated Tumor Control Probability In Sections 4 and 6 we have computed and estimated
values for the TCP and NTCP with different models. For an effective treatment we do not only have
to increase the TCP but also keep the NTCP at a minimum. Therefore, we introduce the uncompli-
cated tumor control probability (UTCP) which is a general expression for the probability of achieving
complication-free tumor control [34].
In general, the UTCP can be described as the probability for tumor control (denoted with P (C)) minus
the probability that the patient suffers severe health impairment (denoted with P (I)) but is controlled:
UTCP = P (C)− P (C ∩ I), (18)
where P (C ∩ I) denotes the probability that the tumor is controlled and the patient suffers health
impairment [1]. With the multiplication law of statistics, we can rewrite (18) as
UTCP = P (C)− P (C)P (I|C) = P (C)(1− P (I|C)),
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where P (I|C) is the conditional probability for injury provided the tumor has been controlled. When the
event of an injury I and the event of tumor control C are statistically independent we obtain P (I|C) =
P (I). Thus we obtain
UTCP = P (C)(1− P (I))
which is
UTCP = TCP (1−NTCP) (19)
with our notations from the previous sections. Figure 14 shows results obtained by simulating the
previous therapy strategies relying on (1) and (12). Averages are taken over 103 simulations. The results
suggest that time-discrete therapies start becoming a more effective option after the half time of overall
treatment, while continuous time approaches seem to be adequate only during the earlier treatment phase,
though their UTCPs are quite low. Moreover, the UTCP of radiotherapy alone or applied concurrently
with the differentiation promoter seems to perform better than that of alternative chemo-radiotherapy,
which suggests that at least in the continuous case the use of a differentiation promoter is questionable.
However, as mentioned previously, radiotherapy is actually applied in a time-discrete way. The UTCP
obtained in this case also suggests that the application of a differentiation promoter as sole chemotherapy
might not lead to substantial benefit (at least when compared with radiotherapy); it is merely the earlier
onset of positive therapeutic effects which could justify its use.
Figure 14: UTCP for the different treatment strategies based on 103 simulations of (1) and (12).
Probably therapeutic schemes involving further combinations of radiotherapy, differentiation promoter(s),
and chemotherapy effectively aiming at direct or indirect tumor cell kill (e.g., by inhibiting angiogenesis)
might be more appropriate. The performance of one scheme or the other may also vary according to the
type of cancer to be treated, and it may be necessary to include various other features of the specific
therapeutic approach(es) to be applied. Our goal was not to identify the best therapeutic option, but
rather to provide a model class which is able to combine the description of the evolution of tumor cell
subpopulations having different, dynamically changing phenotypes, with a large variety of therapeutic
schedules, thereby explicitly accounting for stochasticity, and illustrate it for several therapy approaches,
both time-discrete and continuous.
7 Assessment of future average development of tumor and nor-
mal tissue via PDEs.
In this section we want to address the problem of assessing the mean evolution of tumor and normal tissue
with respect to time and to cell populations which at a specified moment in time can vary continuously
in a given set of states. To this aim we deduce PDEs characterizing the dynamics of variables of interest
related to the three (sub)populations of cells: CSCs, DCs, and normal cells.
We start with the SDE system obtained by coupling (1) with (12) and describing tumor and normal cell
evolution in the absence of therapy:
dc(t) = µ1(c, s)dt+B11(c, s)dW1(t) +B12(c, s)dW2(t) (20a)
ds(t) = µ2(c, s)dt+B21(c, s)dW1(t) +B22(c, s)dW2(t) (20b)
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dn(t) = (bn(n)− dn(c, s))n(t)dt+
√
(bn(n) + dn(c, s))n(t)dW3(t), (20c)
with initial conditions
c(t0) = c0, s(t0) = s0, n(t0) = n0, (21)
and with the involved coefficients µi, Bij (i, j ∈ {1, 2}), bn, dn as in Subsection 2.1 and Section 5.
Thereby, Wi(t) (i = 1, 2, 3) are as before mutually independent Wiener processes. Note that here t0 is
a reference time (for example, the time when the tumor was first discovered and documented, with an
appropriate staging system, by a physician) and not necessarily the initiation time point of the disease.
Then starting from the information available about the tumor at t0 we want in this section to describe
his future mean evolution with a PDE.
In the following we will be rather interested in characterizing the behavior of the whole tumor burden, its
stemness portion, and the difference between the amount of normal tissue and the latter’s critical density
involving the functionality threshold γ considered in Section 5 and thus allowing to evaluate the survival
chances of a patient. Therefore we consider the function f : R3 → R3,
f(ct, st, nt) := (ρt, st, ϑt)
t, where ρt := ct + st and ϑt := nt − γnH .
Thereby nH denotes the (constant in time) amount of normal tissue.
Let Xt := (ct, st, nt)
t and Yt := (ρt, st, ϑt)
t. Then applying Itô’s formula for the process Yt = f(Xt) we
get the corresponding SDE system:
dYt = lµ.. (Yt)dt+ pσ(Yt)dW(t) (22)
Yt0 = y,
with the initial condition y = (c0 + s0, s0, n0 − γnH)t, drift lµ.. (Yt) =





bn(Y3(t) + γnH)− dn(Y1(t), Y2(t))
)
(Y3(t) + γnH), and diffusion matrix
pσ(Yt) =





bn(Y3(t) + γnH) + dn(Y1(t), Y2(t))
)
(Y3(t) + γnH). If (Yt)t≥0 is a solution to (22) on
a filtered probability space (Ω,A,P) then (see e.g. [51]) (Yt)t≥0 is a Markov process relatively to that
filtration, having a semigroup (St)t≥0 defined, for any function φ measurable and bounded on R3, by
Stφ(y) = E[φ(Yt)|Yt0 = y].

















Then (see e.g. [51]) the quantity U(t,y) := E[φ(Yt)|Yt0 = y] satisfies the backward Kolmogorov PDE
∂tU(t,y) = LU(t,y)
U(t0,y) = φ(y).
This is written for convenience as a system, however, the three PDEs are actually decoupled.
Here we will choose for φ the identity mapping on R3, so that we obtain for U(t,y) = E[Yt|Yt0 = y] the
















U(t0,y) = y. (23b)
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Thus, the solution of this PDE represents the vector of expected overall tumor burden, the expected
density of stem cell subpopulation, and the expected dynamic displacement from the critical functionality
level of normal tissue. All these quantities depend on time and on the starting distributions of the cell
populations c0, s0, n0, all of which are supposed to be positive and to have finite upper bounds, say Mc,
Ms and Mn, respectively. The sign of the third component of U can be negative or positive, according
to whether the normal tissue falls or not below the critical level and it is actually an indicator of patient
survival, therefore arguably more relevant than the corresponding effective amount of normal tissue. Also







































U(t0,y) = y. (24b)
Alternatively a backward problem with terminal condition can be obtained (see e.g. [51]) by considering
u(τ,y) := E[YT |Yτ = y], t0 ≤ τ ≤ T, (25)















(τ,y) = 0 in (t0, T )×D (26a)
u(T,y) = y in D, (26b)
together with boundary conditions like those mentioned above. Equation (25) defines the expectations of
the quantities of interest ρt, st, ϑt (overall tumor burden, density of stem cells, and dynamic displacement
from the critical functionality level of normal tissue) at some later time T provided they were known
at some earlier time τ . In our context, the latter could be the time of diagnosis (usually differing from
patient to patient) and T could correspondingly represent the follow-up time. Note that (26) can be
reduced to the class of PDEs of type (23) by the transformation U(T + t0 − τ,y) := u(τ,y).
Including therapeutic effects can be easily done for continuously applied therapies, as in the SDE frame-
work we accounted for such effects by way of the coefficients in the SDEs involving birth, death, and
transition rates affected by the respective therapeutic agent. Time-discrete therapies with ionizing radi-
ation applied at discrete, pre-specified times can be described in this context similar to what we did in
Subsection 3.4, i.e. using some stochastic processes Lt to characterize the cumulative treatment effect
on the quantities given by the components of the vector U(t,y) (or for that matter u(T + t0 − t,y))
determined by solving the above initial (or, correspondingly, terminal)-boundary value problem. For
instance, instead of (9) we could consider
Rρ(t,y) = (U1 − U2)(t,y)e−εcL
(c)
t + U2(t,y)e






t as in Subsection 3.4 and use these to dynamically replace the initial conditions for U1
and U2 on every new computed time interval. We only describe the concept here and address explicitly
merely the case without therapy in order not to overload the presentation.
7.1 Numerical simulations
System (24) involves three PDEs, each of the solution components depending on time and on a three-
dimensional vector y. However, taking a closer look at the original SDE system (20) we see that the
third equation is decoupled from the first two. This observation can help to reduce the computational
effort needed for solving (24). Indeed, similarly with what we did above, we can write a PDE system for
Ũ(t, ỹ) = (U1(t, ỹ), U2(t, ỹ))







































· ∇Ũ(t, ỹ) in (t0, T )× R2+,
Ũ(t0, ỹ) = ỹ in R2+, (27b)













This system of decoupled, linear PDEs is nonautonomous with respect to the two-dimensional ỹ variable
and can be solved to provide at any time the expected total tumor burden and the expected amount of
stem cells in that tumor.
To determine the quantity U3(t,y) = E[Y3(t, ỹ)|Y3(t0) = y3] we need the full vector y, thus the corre-










(y) in (t0, T )× R3 (29a)
U3(t0,y) = y3 in R3. (29b)
The solution will be computed on D = D̃× (−γnH ,Mn − γnH). We use a Douglas-Rachford alternating
direction (ADI) finite difference method which makes one dimension implicit at each time step, while
leaving the other two dimensions explicit. Here a more accurate ADI scheme (see [14]) has been imple-
mented and employed to find the approximations of the solution components. The parameters involved in
the coefficients of the PDEs are the same as those used in Sections 2 and 5. Figure 15 shows the solution
components at different times: U1: expected total tumor burden, U2: expected amount of tumor stem
cells, and U3: expected deviation of normal cells/tissue from the critical level at which the affected region
is still functional. The latter was taken to be γ = 0.7, i.e. 70% of the normal cells have to be preserved
in order to ensure tissue functionality. Notice that with time passing the normal tissue is more and more
degraded, as a consequence of the interaction with tumor cells. Increasing the functionality threshold
drives U3 into the negative region, meaning that patient survival chances are dramatically impaired. Such
a situation is illustrated in Figure 16, where γ = 0.85, while the rest of the parameters remain unchanged.
Only U3 is represented, as U1 and U2 do not change with γ due to the normal cells not influencing the
evolution of tumor cells.
7.2 Analytical approximations based on Euler SDE discretization
In this subsection we describe a way to derive closed-form analytical approximations of the predicted
mean of YT based on the staging of the tumor at τ , i.e. for u(τ,y) = E[YT |Yτ = y] with τ ∈ [t0, T ] and
y ∈ R3+. However, in order to simplify the presentation we will only illustrate the method for the vector
of the first two components u1, u2, hence corresponding to the solution of the PDE system














(τ, ỹ) = 0 in (t0, T )× R2+ (30a)
ũ(T, ỹ) = ỹ in R2+, (30b)
where t0 represents the initiation time of the tumor. For simplicity of notation we will omit the tildes on
the variables in the following, but always mean the 2D vectors, unless otherwise stated. In the following
we give an analytical approximation of the solution to (30) on a small prediction interval (τ, T ).5 The
idea presented here can be recursively extended such that the corresponding results hold on an arbitrary
prediction interval (τ, T ), however, they would have a very cumbersome closed form.
Proposition 7.1 Let z := (ln y1, ln y2)
t, y := (y1, y2) ∈ R2+. Then an analytical approximation of the


















Figure 15: Solution components of (27) and (29) at various time moments, no therapy applied. Left
column: expected total tumor burden, middle: expected density of cancer stem cells, right: expected
deviations of normal cells from critical threshold for which γ = 0.7. Plots 15(a)-15(c): initial state,
15(d)-15(f): 10 days, 15(g)-15(i): 30 days, 15(j)-15(l): 70 days.
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(a) (b) (c)
Figure 16: Solution of (29) at different times, with no therapy applied. Shown are expected deviations













where j = 1, 2 and we used the following notations (ζ ∈ R2):
A(ζ) :=
(












M(ζ) := ζ + A(ζ)ð, Σ(ζ) :=
(
e−ζ1 p̃σ11(ζ) e−ζ1 p̃σ12(ζ)
e−ζ2 p̃σ21(ζ) e−ζ2 p̃σ22(ζ)
)






















δj := (δj1, δj2)




Thereby, l̃µ.. and p̃σ are as in (28), S·j denotes the column j of S, and as usual A : B = trace(ABt) for
A,B arbitrary matrices.
Proof: Let Zj(τ) := lnYj(τ), j = 1, 2. Then uj(τ,y) = E[eZj(T )|Z1(τ) = ln y1, Z2(τ) = ln y2]. The SDE
system satisfied by Z = (Z1, Z2)
t reads
dZt = A(Zt)dt+ Σ(Zt)dW(t), (33a)
Zτ = z, t ∈ [τ, T ], (33b)
where z = (ln y1, ln y2)
t, and the drift and diffusion coefficients A(Zt) and Σ(Zt) are those given in (31)
and (32), respectively. In general, the discretization of (33) has the form
Zτk+1 = Zτk + A(Zτk)ð + Σ(Zτk)
√
ðεk, εk ∼ N(0, I2), k = 0, . . . , n− 1, (34)
where τ = τ0 < τ1 < · · · < τn = T and ð = τk+1 − τk = T−τn .
We aim at computing the approximation







where z(0) = z and pτ,T is the transition density from τ to T for the Markov process given in (34).









(1)|z(0))pτ1,τ2(z(2)|z(1)) . . . pτn−1,τn(z(n)|z(n−1)) dz(1) . . . dz(n) (36)
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and consider that pτk,τk+1(z
(k+1)|z(k)) is the density of a normal distribution of mean M(z(k)) and variance











for all z(k+1) ∈ R2, k = 0, . . . , n− 1.
To compute (35) recall that we consider for the sake of clarity n = 2; the computations for the more
general case are analogous, but more tedious.




















(2)|z(1)) dz(2) dz(1). (37)
To calculate the inner integral in (37) observe that it is the Laplace transform of a multivariate normal
density. Denoting δj := (δj1, δj2)




















Plugging this into (37) gives












We expand the exponential of the nonlinear part from the above integral in a Taylor series of second
order around the point M(z(0)),6 then use the Laplace transform for a multivariate normal distribution































, r, s = 1, 2.



















, j, r = 1, 2








j, r, s = 1, 2. Replacing into (38) gives the claim, after rewriting the obtained formula with the aid of
matrix-vector multiplications. 
8 Conclusions and outlook
Noise is an important component of all physiological processes. In cancer development and treatment
it plays an important role, too, as there is a large patient-to-patient variability concerning both the
evolution of a tumor and its response to therapy. Moreover, cell population reduction effected by therapy
leads to small cell numbers and thus to fluctuations. In this work we proposed a modeling approach
involving SDEs and obtained from simple transition probabilities, thereby paying particular attention to
the deduction of the SDEs. The explicit drift and diffusion terms are derived from step-by-step modeling
and not by simply adding some multiplicative noise to an ODE system describing in a more or less heuristic
6Actually a Taylor expansion of any order can be used and all computations can be performed explicitly in an absolutey
analogous way, however they can become very involved, therefore we restrain here to this second order expansion.
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way the evolution of the tumor cell subpopulations. For instance, the form of the (negative) diffusion
coefficients for the model in [49] is largely arbitrary and needs justification. The same applies to the
simple multiplicative form of (positive) diffusions in the models from [52, 65]. We would like, however,
to mention here the model in [56] focusing on another issue related to tumor growth and effectively
deducing the coefficients of the corresponding single SDE by a diffusion limit of branching processes. The
deduction method we used here is related to that in [56] and similar to what has been done in [2] for an
SDE system characterizing the dynamics of interacting populations, however with relevant modifications
aiming at preserving the positivity of solutions. Indeed, the conditions for the latter were shown in [10]
to be necessary and sufficient, therefore they actually guided the modeling, in particular by requiring
some of the mitotic and differentiation rates to be nonconstant.
Further factors from the tumor microenvironment, e.g., tumor acidity, affect cell proliferation, differen-
tiation, and therapeutic response of both normal and neoplastic tissues. Such effects can be included
by considering a supplementary (deterministic or stochastic) equation for the dynamics of proton con-
centration and modifying the cell splitting rates to let them depend not just on the available amount of
cells, but also on the acidity. Birth and death rates could depend on the latter as well. An SDE system
with correlated Wiener processes would be more realistic, but also more challenging, as the theory and
numerics of such systems still have to be developed for the situation where the SDEs are coupled in such
nonlinear way as is the case here.
Even for a nonlinear SDE system like ours, with independent Brownian motions characterizing the noise
there are still enough open problems: The solutions can be shown to exist only locally, the numeri-
cal schemes available so far are not positivity preserving, and, moreover, the system can become stiff
when small cell densities are reached simultaneously in both subpopulations, leading to large diffusion
coefficients needing to be balanced by a tiny discretization step.
Passing to a PDE system like in Section 7 enables accounting for the (expected) evolution of tumor
cells in interaction with the surrounding normal tissue not only with respect to time, but also depending
on continuous ranges of tumor and (shifted) normal cell densities, so that predictions become available
for different scenarios of the tumor and normal tissue states, thereby also making allowance for tumor
heterogeneity with respect to stemness. Similarly, other cell phenotypes can be considered in this modeling
framework, e.g. if one is interested in the migratory (mesenchymal vs. amoeboid, moving vs. proliferating,
etc.) behavior of tumor cells in order to assess not just growth, but also spread of the neoplastic tissue.
Indeed, besides time evolution the space dynamics also plays an essential role in the assessment of several
indicators of tumor malignancy, among others acidity, cell motility, and tissue degradation. In particular,
radiotherapy needs a correct estimation of tumor margins for determining the CTV/PTV7. For instance,
this issue is of outmost relevance for cancers like glioma, whose spread heavily relies on the underlying,
highly anisotropic and patient-specific brain tissue structure. Accounting for such effects leads to systems
of partial differential equations of reaction-diffusion-taxis type, some coupled to ODEs. Accounting for
stochasticity in that context is far more challenging, and even with major simplifications there are but
few references addressing such models. They involve PDEs with random coefficients [29, 30] or couplings
between PDEs and SDEs [28, 38]. The latter, however, only take into account a single cancer cell
population moving and proliferating under the influence of intra- and extracellular tumor acidity, and were
obtained in a heuristic way. Effectively deducing adequate coupled PDEs from transition probabilities for
interacting cell subpopulations inferring phenotypic switch triggered by randomly influenced population
densities or just by some external factors would be a most interesting, but also challenging issue even if
only done formally.
Still in the present framework of interacting cell populations just depending on time, the issue of cancer
stem cell plasticity in which tumor cells harbor the dynamic ability of shifting from a non-CSC state
to a CSC state and back gives rise to more complicated two-way couplings, therefore we made here the
simplifying assumption that CSCs only divide symmetrically or asymmetrically and cannot arise from
differentiated cells. Including CSC plasticity can be, however, of substantial relevance to the therapeutic
outcome [42] and as such deserves investigation. Mathematical models have the great advantage of being
amply versatile and allowing to test a large variety of approaches with features which can be turned on
and off at will in the simulations. Therefore, they have the potential of helping to understand both the
modeled processes and the performance of the therapeutic approach.
7CTV: clinical target volume, PTV: planning target volume
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9 Appendix
9.1 Recalling invariance criteria for SDEs
In this appendix we recall the result of [10] concerning stochastic invariance.
Let (Ω,F ,P) be a probability space with a right-continuous increasing family F = (Ft)t≥0 of sub-σ fields
of F , each containing all sets of P-measure zero. We consider an SDE system of the form
dX(t) = f(t,X(t))dt+ g(t,X(t))dW (t), t ∈ (0,∞), (39)
X(0) = X0,
where f : [0,∞) × Rm → Rm and g : [0,∞) × Rm → Rm×r are locally Lipschitz continuous in the
X-argument and continuous w.r.t. t, whereas W : [0,∞) × Ω → Rr is an r- dimensional F - adapted
Wiener process.
Definition 9.1 ([10]) The subset K ⊂ Rm is called invariant for the system (39) if for every X0 ∈ K
the corresponding solution (X(t))t≥0 satisfies
P ({X(t) ∈ K, t ∈ (0,∞)}) = 1.
Theorem 9.1 ([10]) Let I ⊂ {1, . . . ,m} be non-empty. Then the set
K := {x ∈ Rm : xi ≥ 0, i ∈ I}
is invariant for the stochastic system (39) if and only if
fi(t, x) ≥ 0 for x ∈ K s.t. xi = 0,
gij(t, x) = 0 for x ∈ K s.t. xi = 0, j = 1, . . . , r
for all t ≥ 0 and i ∈ I.
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